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Abstract
The strongest BMI–associated GWAS locus in humans is the FTO gene. Rodent studies demonstrate a role for FTO in energy
homeostasis and body composition. The phenotypes observed in loss of expression studies are complex with perinatal
lethality, stunted growth from weaning, and significant alterations in body composition. Thus understanding how and
where Fto regulates food intake, energy expenditure, and body composition is a challenge. To address this we generated a
series of mice with distinct temporal and spatial loss of Fto expression. Global germline loss of Fto resulted in high perinatal
lethality and a reduction in body length, fat mass, and lean mass. When ratio corrected for lean mass, mice had a significant
increase in energy expenditure, but more appropriate multiple linear regression normalisation showed no difference in
energy expenditure. Global deletion of Fto after the in utero and perinatal period, at 6 weeks of age, removed the high
lethality of germline loss. However, there was a reduction in weight by 9 weeks, primarily as loss of lean mass. Over the
subsequent 10 weeks, weight converged, driven by an increase in fat mass. There was a switch to a lower RER with no
overall change in food intake or energy expenditure. To test if the phenotype can be explained by loss of Fto in the
mediobasal hypothalamus, we sterotactically injected adeno-associated viral vectors encoding Cre recombinase to cause
regional deletion. We observed a small reduction in food intake and weight gain with no effect on energy expenditure or
body composition. Thus, although hypothalamic Fto can impact feeding, the effect of loss of Fto on body composition is
brought about by its actions at sites elsewhere. Our data suggest that Fto may have a critical role in the control of lean mass,
independent of its effect on food intake.
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Introduction
The fat mass and obesity-associated (FTO) gene is an AlkB-like,
Fe(II)- and 2-oxoglutarate–dependent nucleic acid demethylase
that has been shown to demethylate 3-methylthymine and 3-
methyluracil in single-stranded DNA and RNA, respectively [1–
2]. More recently FTO has been demonstrated to demethylate
N6-methyladenosine in nuclear RNA [3].
Several single nucleotide polymorphisms (SNPs) in the first
intron of the FTO gene are associated with obesity and type 2
diabetes [4–7] (reviewed [8–9]). Approximately 16% of individuals
of European descent are homozygous for the at-risk (A) allele, and
have a ,1.67-fold increased risk of obesity, weighing on average
,3 kg more than those with the T allele (rs9939609) [5]. The
effect of FTO on BMI is observed by 7 years of age [5]. A study
looking at BMI from early infancy to 13 years old has revealed a
more complex pattern with the rs9939609 A allele associated with
lower BMI before the age of 2.5 years and then a positive
(increased BMI) association after the age of 5.5 years [10]. This
appears to be due to an earlier adiposity rebound (normal BMI
peaks in the first year and then there is decline in adiposity up to
about 5 years of age after which it then increases (rebounds) again)
in individuals with the A allele [10–11]. Life course studies with
rs9939609 show BMI association strengthening during childhood
and adolescence up to a peak around 20 years of age and then
declining [12].
A homozygous R316Q enzyme inactivating mutation resulted
in a broad spectrum of clinical manifestations including severe
intrauterine growth retardation and death before the age of three
[13]. The early developmental effects of FTO mutations and the
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profile of BMI effects of FTO risk alleles in children and young
people suggest that FTO may be important in development in utero
and early life. However, it is noteworthy that heterozygous loss-of-
enzymatic-function mutations can occur in both lean and obese
individuals [14].
Many human population studies have shown that at least some
FTO effects may be mediated through increased food intake (in
some cases of high fat or more palatable food) and effects on
hunger and satiety responses [15–22]. However, a high fat diet
and inactivity may instead be a modifying factor interacting with
FTO genotype [23–25].
In the mouse, two constitutive knockout alleles have been
reported (Ftotm1Urt and Ftotm1.1Pzg), both of which cause postnatal
growth retardation and high postnatal mortality rates [26–27]. In
one of these studies there was significant reduction in adipose
tissue and lean body mass that was attributed to increased energy
expenditure despite relative hyperphagia [26]. However, this study
used division by lean body mass to account for the changed body
composition, rather than multiple linear regression of body
composition parameters using ANCOVA as is commonly used
in human studies [28–30]. This led to much discussion in the
literature of energy expenditure normalization methods. In the
second study, body composition was relatively normal although
there was lower body weight, lower bone mineral density, shorter
body length and relative hyperphagia [27]. Energy expenditure
was increased, both when determined by ratio analysis against lean
mass as well as ANCOVA. Deletion of Fto in neurons (using
Nestin-Cre) caused a similar phenotype, demonstrating a key
neuronal role for FTO in postnatal growth [27]. A third loss-of-
function mouse model comprising a dominant missense mutation
in the C-terminal of the mouse Fto gene resulted in reduced weight
and fat mass and increased energy expenditure without the
increased perinatal death and growth retardation [31]. In contrast,
a mouse model that globally overexpressed FTO showed increased
food intake, body weight and fat mass [32].
These animal models clearly indicate a role for Fto in energy
metabolism, but many questions remain unresolved, including
whether there is any effect on energy expenditure, what the role of
Fto is in early life and in the adult, which tissues are involved,
which regions of the brain contribute to the phenotype and what is
the cellular role of FTO.
In our studies we sought to resolve the question of energy
expenditure in global germline knockout mice. We found no
evidence for increased energy expenditure in this or our other two
models analysed using ANCOVA. We used our conditional mouse
knockout allele with a tamoxifen inducible Cre recombinase to
circumvent the perinatal lethality and growth retardation observed
in global germline knockouts in order to investigate the role of
FTO in adult animals. In adult onset global knockout mice we
observed reduced body weight with later weight convergence and -
surprisingly - reduced lean mass and increased fat mass. The latter
explains the later weight convergence. We further asked whether
these effects were due to loss of FTO in mediobasal hypothalamic
regions of the brain and found that these mice were only mildly
affected, suggesting a role for FTO in brain regions other than the
hypothalamus.
Results
In order to investigate the function of the Fto gene in the mouse
we constructed mice carrying a LoxP-flanked (floxed) exon 3
frameshift allele (Figure S1A). These mice were used to generate
animals in which Fto was knocked out in all tissues either prior to
birth or in adult life. Male mice were used in global germline
knockout and adult onset knockout experiments and female mice
in adult onset hypothalamic knockout experiments.
Global Germline Knockout Results in Perinatal Lethality
and Reduced Size
Fto exon 3 and the PGK-neomycin selection cassette were
excised by Cre recombinase, under the control of the b-actin
promoter, to generate a constitutive global germline Fto knockout
(germline KO) allele (Figure S1A). Heterozygous germline KO
mice were intercrossed to generate heterozygous (Fto+/2), homo-
zygous (Fto2/2) and wild-type (Fto+/+; WT) littermate controls.
Deletion of Fto exon 3 was shown by RT-PCR (data not shown)
and loss of FTO protein expression was confirmed by immuno-
blotting (Figure S1B).
Homozygous germline Fto2/2 mice show perinatal lethality
with only 45% surviving to weaning (data not shown). Body weight
was measured weekly from 4 to 20 weeks of age. Male Fto2/2 mice
weighed significantly less than WT littermates at all ages being
approximately 13% lighter at 20 weeks (Figure 1A, Table S1).
Additionally, Fto2/2 mice displayed growth restriction (anus to
nose length approximately 0.7 cm shorter) when compared to WT
littermates (Figure 1B). Body composition, as determined by dual
energy X-ray absorptiometry (DEXA), showed a reduction in fat
and lean mass in KO males when compared to WT littermates
(Figure 1C, 1D). When corrected for body weight, the percentage
reduction in fat mass was not significant but lean mass was
significantly reduced (by 11.5% in males; p = 2.50E-05 by Welch t-
test of raw data, p = 0.02 after multiple linear regression
normalisation for body weight Table S2). Measurement of glucose
tolerance in a 30-minute intraperitoneal glucose tolerance test
(IPGTT) showed some evidence of improved tolerance in male
homozygotes (Figure 1E).
Global Germline Knockout Results in Altered RER and
Unchanged Energy Expenditure
Absolute food intake (g/day) was not significantly different
between homozygous Fto2/2 mice and WT littermates (Figure 1F);
however, relative food intake was increased when normalised for
the significantly reduced body weight (data not shown).
Author Summary
The fat mass and obesity (FTO) gene has one of the
strongest links with body mass index (BMI) in the human
population. One in six people have the ‘‘risk’’ alteration and
weigh 3 kg more than those with the unaltered gene, but it
is not understood how this gene influences BMI and obesity.
We set out to understand how and where in the body FTO
affects food intake, energy expenditure, and body compo-
sition using a mouse model that can be manipulated to lack
FTO at particular times and/or places. Removing FTO
everywhere from conception had a dramatic effect on body
composition and resulted in stunted growth and some
lethality. Removing FTO everywhere but only in adult
animals resulted in better viability and normal growth but,
surprisingly, reduced lean mass and increased fat mass with
a change in the type of metabolic fuel being used. Finally,
we removed FTO from the hypothalamus of adult animals,
an important brain region involved in energy metabolism.
These animals showed a mild reduction in food intake and
weight gain. Our experiments show that FTO has an
important role in body composition and that other brain
areas outside of the hypothalamus are also important in
determining its effects.
Adult Onset Loss of FTO
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Oxygen consumption, corrected for lean body mass, was
increased in homozygous male Fto2/2 mice in both the light
and dark phases, but the difference was statistically significant only
in the light phase (Figure 2A, Table S3). Carbon dioxide output
and energy expenditure, both lean mass corrected, were not
significantly different (Figure 2B, 2C, Table S3). However, the
RER was significantly reduced in both light and dark phases
(Figure 2D, Table S3).
There has been much discussion in the literature of the correct
way to normalise energy expenditure data for FTO KO mice [28].
Because our mutant mice are substantially lighter than their WT
littermates we compared linear regression and ratio normalisation
methods (Figure 3A–3E). To illustrate the differences between these
two methods, we plotted energy expenditure against lean mass
(Figure 3A). When energy expenditure data are not corrected
(Figure 3B), WT mice exhibit higher mean energy expenditure than
KO mice (although the difference is not statistically significant with
our sample size). However, as Figure 3A shows, WT mice have
higher lean mass, and lean mass positively correlates with energy
expenditure. Consequently the difference in energy expenditure
disappears upon regression adjustment for lean mass (Figure 3C).
The difference in regression-adjusted energy expenditure in
Figure 3C is the vertical distance between the two lines in
Figure 3A (see Materials and Methods for details). The ratio-
normalization approach (Figure 3D, 3E) over-corrects for the effects
of lean mass, leading to artificial inflation of ratio-adjusted energy
expenditure in KO mice relative to WT mice. This problem is now
widely recognized and it is accepted that regression based
adjustment is the most appropriate way to account for differences
in body weight or composition, as has been the case in human
studies for many years [29–30]. We conclude that in our global
germline knockout there is no detectable difference in energy
expenditure rate between knockout and WT littermates.
Our global Fto germline knockout exhibits many similarities to
the two other published Fto knockouts [26–27]. However, as all
these models show considerable perinatal lethality and growth
restriction it is difficult to determine the precise role of FTO in
body composition and metabolism. In order to circumvent early
Figure 1. Body weight, body composition, and food intake in male global germline Fto Knockout mice. A, Male body weight WT Fto+/+,
(n = 10), Fto2/2 (n = 10), B, Body length WT Fto+/+, (n = 14), Fto2/2 (n = 8), C, Fat mass in males at 20 weeks of age, WT Fto+/+, (n = 17), Fto2/2 (n = 8), D,
Lean mass in males at 20 weeks of age, WT Fto+/+, (n = 17), Fto2/2 (n = 8), E, Intraperitoneal glucose tolerance test (IPGTT) area under the curve (AUC)
in males at 16 weeks of age. WT Fto+/+, (n = 9), Fto2/2 (n = 10), F, Food intake in male mice at 10 weeks of age during a 24-hour period in metabolic
cages. WT Fto+/+, (n = 12), Fto2/2 (n = 9). Data are expressed as mean 6 SE and in B–F individual data points are shown. Time-course data were
analysed using the repeated-measures ANOVA model (see Materials and Methods) (A). The other comparison p-values (B–F) correspond to a Welch t-
test of the null hypothesis of no difference between genotypic groups. *P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pgen.1003166.g001
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postnatal and developmental effects that lead to lethality and
growth restriction as a result of FTO loss, we therefore inactivated
Fto in adult mice.
The Severe Lethality Seen with Germline Fto Loss Is Not
Seen in Adult Onset Loss
Mice carrying the conditional floxed Fto allele were crossed with
mice carrying a tamoxifen-inducible ubiquitin-Cre recombinase and
the resulting heterozygous mice carrying Cre recombinase inter-
crossed to generate homozygous floxed Fto mice and homozygous
mice carrying both floxed Fto and Cre recombinase. Mice carrying
Cre recombinase alone were bred from the heterozygote population
by crossing with WT mice. All mice were on a congenic C57BL/6J
background. Mice of all genotypes were treated with tamoxifen or
vehicle at 6 weeks of age (around the time of sexual maturity) by oral
gavage daily for five days. This led to global (as ubiquitin is expressed
in most, if not all, tissues) deletion of Fto in mice carrying both floxed
Fto and Cre recombinase: we refer to these as adult onset KO mice.
Inactivation of the Fto gene and loss of FTO protein was
demonstrated by immunoblotting for FTO (Figure S2).
There were 3 unexplained deaths out of 25 adult onset KO
mice (12%) over the 14 weeks after tamoxifen treatment, and one
death in the vehicle control group (n = 11, 9%). This indicates
substantially improved viability compared with germline KO mice
(45% lethality). Whether the 3 deaths in adult KO onset mice are
related to Fto deletion or are chance events is unknown.
Repeated measures analysis comparing post-treatment body
weight data from vehicle-treated mice carrying both Cre and
floxed Fto alleles (Vehicle) and tamoxifen-treated Cre mice
(Tamoxifen) did not show significant differences in weight
(p = 0.89). We therefore present below only data on male mice
carrying both the floxed Fto allele and Cre recombinase, which
have either been treated with tamoxifen (Adult onset KO) or with
the corn oil and 2% ethanol vehicle (control).
Adult Onset KO Mice Have Reduced Body Weight and No
Growth Retardation
Mice were weighed weekly from 3 weeks of age. In the weeks
prior to treatment (weeks 3 to 6) there was no statistical difference
between groups (Figure 4A; Table S4). Mice were treated with
Figure 2. Energy expenditure and metabolism in male global germline Fto KO mice. A, VO2 consumed, B, VCO2 produced, and C, energy
expenditure (EE), adjusted for variation in lean mass using multiple linear regression (ANCOVA). D, respiratory exchange ratio (RER). Measurements
were made in male mice during the light and dark phases at 18-weeks of age. Fto+/+ (n = 20), Fto2/2 (n = 9). Data are expressed as mean 6 SE and
individual data points are shown. For details of the lean-mass adjustment made in panels A–C, see Materials and Methods, *P,0.05, **P,0.01,
***P,0.001.
doi:10.1371/journal.pgen.1003166.g002
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tamoxifen or vehicle at 6 weeks of age. During weeks 7 to 9, the
average rate of weight gain of adult onset KO mice was slower
than that of control mice, leading to a lower mean weight of KO
mice that persisted over the next 12 weeks (Figure 4A). Repeated-
measures ANOVA indicated statistically significant inter-group
differences, with reduced KO body mass relative to controls
(p = 0.0043). Weekly inter-group differences were statistically
significant throughout weeks 8 to 18 (2 to 14 weeks after treatment
started (Time-by-time ANOVA p,0.05; Table S4).
There was no change in body length when measured in
sacrificed animals at 20 weeks of age (Figure 4B).
Adult Onset KO Mice Have Increased Fat and Decreased
Lean Mass
Quantitative NMR was used to determine lean and fat mass
weights at 9 and 20 weeks of age (3 and 14 weeks after treatment
started, Figure 4C, 4D). At 9 weeks of age there was a significant
reduction in lean mass (p = 0.00017), a fall in lean mass as a
proportion of body weight (p = 8.9E-05), a trend to increased fat
mass (p = 0.050), and a significant increase in fat mass as a
proportion of body weight (p = 0.0047), in KO mice compared to
controls (Figure 4C, 4D and Table S2). Using multiple linear
regression to better take account of the body weight differences,
lean mass was significantly decreased (p = 0.0011) and fat mass was
increased (p = 0.024; Table S2). These differences were consider-
ably larger at 20 weeks of age (Body weight adjusted ANCOVA:
lean mass p = 2.0E-09, fat mass p = 5.9E-10, Figure 4C, 4D).
Adult Onset Global KO Mice Do Not Have Increased
Energy Expenditure but Do Show Altered Metabolism
To further understand these weight and body composition
differences we measured food intake and energy expenditure.
There were no significant differences in 24-hour food intake
measurements in metabolic cages at either 10 (Figure 4E) or 19
Figure 3. Adjustment of energy expenditure for lean mass, regression analysis compared to ratio adjustment. A, regression of energy
expenditure against lean mass, B, average energy expenditure, C, energy expenditure values adjusted for lean mass using ANCOVA, D, values for
energy expenditure divided by lean mass and plotted against lean mass to show the effect of ratio adjustment, E, average energy expenditure
divided by lean mass. Data as in Figure 2 for dark phase. The p-values in B,E were calculated using a Welch t-test of the null hypothesis of no
difference between genotypic groups. For lean mass adjustment in C see Materials and Methods. *P,0.05.
doi:10.1371/journal.pgen.1003166.g003
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weeks (data not shown) of age. Adult onset KO mice were
subjected to 24-hour indirect calorimetry at 18 weeks of age and
showed unchanged oxygen consumption and decreased carbon
dioxide output (when adjusted for lean body mass Figure 5A and
5B, Table S3). Energy expenditure adjusted for lean mass was not
significantly different during either light or dark periods (Figure 5C,
Table S3). The RER of adult KO mice was significantly reduced
during both periods and overall (Figure 5D, Table S3).
Adult Onset Hypothalamic Fto Loss Has a Small, but
Significant, Effect on Body Weight due to Decreased
Food Intake
As FTO has been proposed to affect hypothalamic metabolism
control pathways, we next tested whether loss of FTO in the
hypothalamus recapitulated some or all of the adult KO
phenotype. We used adeno-associated viral (AAV) vector delivery
technology of Cre recombinase to delete the Fto gene specifically
within the mediobasal hypothalamus of 9–11 week old female Fto-
floxed mice (Figure S3A–S3H). AAV vectors of serotype 7 were
generated to produce either Cre recombinase (AAV-Cre) or GFP
(AAV-GFP), as previously described [33]. Control experiments
were performed to verify the effectiveness of the AAV-Cre vectors
in removing Fto expression in vivo (Figure S3A, S3B and Figure
S4A, S4B).
Over an 8-week period, AAV-Cre injected mice did not show a
significant difference in weight (Figure 6A, Table S5) although
they gained significantly less body weight than AAV-GFP injected
controls (Figure 6B, Table S6). No clearly demonstrable body
composition difference was seen between the 2 groups on DEXA
analysis (data not shown). Measurement of daily food intake
between days 14–23 post injection revealed that the decreased
weight gain was likely due to a significant reduction in food intake
in animals lacking expression of Fto within the hypothalamus
Figure 4. Body weight, body composition, and food intake of male global adult onset KO mice. A, Weekly body weight of adult onset KO
(n = 15) and vehicle-treated control mice (n = 10), B, Nose-to-anus body length of control (n = 10) and adult onset KO mice (n = 12) at 20 weeks of age,
C, Fat mass was increased in adult onset KO mice (n = 14) compared to controls (n = 10) in 9-week old mice (P = 0.05) and further increased in adult
onset KO mice (n = 12) compared to controls (n = 10) at 20 weeks, D, Lean mass was reduced in adult onset KO mice (n = 14 and n = 12) compared to
controls (n = 10 and n = 10) at both 9 weeks and 20 weeks of age, E, Food intake at 10 weeks of age during a 24-hour period in metabolic cages,
control (n = 10) and adult onset KO mice (n = 14). Data are expressed as mean 6 SE. In B–E, individual data points are shown. Time-course data were
analysed using the repeated-measures ANOVA model, see Materials and Methods (A). The other comparison p-values (B–E), correspond to a Welch t-
test of the null hypothesis of no difference between genotypic groups. *P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pgen.1003166.g004
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(Figure 6C). There was no demonstrable difference in energy
expenditure between sham and Cre-treated mice (Figure 7A–7D,
Figure S5, Table S3). Similar effects were seen in male Fto-floxed
mice (data not shown).
Discussion
The phenotype of our mouse carrying a constitutive global KO
of Fto is very similar to the two previously published models [26–
27]. They showed marked perinatal mortality and a clear
divergence of body weight from controls early in the perinatal
period [26–27]. This may reflect changes that occurred in utero
and/or a requirement for FTO from birth.
There has been some discussion about the most appropriate
way to correct energy expenditure for differences in body weight
and composition in both Fto KO mice and mouse models in
general [28,30,34–35]. Using multiple linear regression to control
for variation in lean mass, we found no significant difference in
energy expenditure between the KO and littermate controls in
both light and dark phases. This is in contrast to the study by Gao
et al. [27] who reported an increased energy expenditure tested by
ANCOVA. Using the ratio method, in which data were analysed
by dividing energy expenditure by lean mass, our results show
increased energy expenditure in line with both previous studies.
However, ratio analyses are confounded by the very different lean
masses of the knockout and littermate control groups [26–27].
ANCOVA analysis, which is more correct, reveals that our
germline KO mice show no differences in energy expenditure.
The different result obtained by Gao et al. [27], is likely to be
explained by differences in body composition in their mouse
model.
To avoid the high perinatal lethality of germline KO mice, and
to address the role of FTO gene in adult mice, we generated an
inducible global KO mouse and inactivated the Fto gene at 6
weeks of age. These mice showed much improved viability
compared to mice with a germline KO of Fto. However, some
increased mortality with respect to controls remained. The cause
of this remains unclear and prior to their deaths the mice were not
reported to have been unwell at daily check. Given the phenotype
of children with enzymatic null mutations, one may speculate that
the demise of the 3 mice in question could have been linked to a
cardiac phenomenon but this is far from certain.
Figure 5. Energy expenditure and metabolism of male global adult onset KO mice. A, VO2 consumed, B, VCO2 produced, and C, energy
expenditure (EE), adjusted for variation in lean mass using multiple linear regression (ANCOVA). D, respiratory exchange ratio (RER). Adult onset KO
mice (n = 12) control mice (n = 10). Measurements were made over a 22-hour period during the dark and light phases in 18-week old mice. Data are
expressed as mean 6 SE and individual data points are shown. For details of the lean-mass adjustment made in panels A,B,C, see Materials and
Methods, *P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pgen.1003166.g005
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Adult onset KO mice showed a reduction in body weight in
the weeks immediately following gene deletion, but conver-
gence of body weight towards the last 4 weeks of the study (17–
20 weeks of age). The lower weight is consistent with data from
both our own and published germline global KO mice.
Interestingly, in a previous study, female germline global Fto
KO mice also showed convergence of body weight with
controls by about 13 weeks of age [27]. Energy expenditure
in 18-week old mice, when adjusted for lean mass variation
using multiple linear regression, was not significantly different
between the two groups. We also did not detect any significant
differences in 24-hour food intake measurements. It would be
interesting to know if the differences in body weight are due to
changes in food intake or expenditure - small differences in
these parameters (too small to detect in our experiments) could
have a cumulative effect over a long time period. Other possible
explanations for the reduced body weight include changes in
the efficiency with which energy is extracted from food and
changes in metabolism.
The significantly reduced lean mass at 9 and 20 weeks of age in
adult onset KO mice (compared to controls) is consistent with data
from the germline KO mice. This derives from a lower rate of gain
of lean mass rather than lean mass wasting. The most striking
observation in the adult onset KO mice was the marked gain in fat
mass (both fat weight and fat expressed as a percentage of body
weight increased). By 20 weeks of age the fat weight in the adult
onset KO was almost double (1.926) that of controls. This
contrasts with all three constitutive KO models, which showed a
reduction in fat mass. Given the lower rate of gain of lean mass it
would be interesting to look at the effect of Fto loss in older animals
in which growth had plateaued to examine how the loss of Fto
affects established body composition.
When body weight was taken into account, neither our germline
global KO mouse nor that of Gao et al. [27] showed any difference
in the percentage of fat mass in males. However, in the latter
study, female mice showed a significant increase in percentage fat,
consistent with our adult onset KO mice. The gain in fat mass in
adult onset KO mice was more significant at 20 weeks of age when
Figure 6. Body weight, weight gain, and food intake in female adult hypothalamic KO mice. A, Body weight post injection, B, change in
body weight after injection of either an AAV-GFP (Sham) or AAV-Cre (Cre) vectors, C, Average daily food intake between days 14 and 23 post surgery.
AAV Cre treated (n = 10) and Sham control (n = 11). Data are expressed as mean 6 SE and in C individual data points are shown. Time-course data
were analysed using the repeated-measures ANOVA model, see Materials and Methods (A,B). The average food intake p-value (C) corresponds to a
Welch t-test of the null hypothesis of no difference between genotypic groups, **P,0.01.
doi:10.1371/journal.pgen.1003166.g006
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body weight differences were smaller. Thus, the lower weight of
adult onset KO mice appears to be due, at least in part, to a lower
lean body mass. Further, due to a redistribution of lean mass and
fat mass, combined with an increase in fat mass, body weight was
no longer significantly different in adult onset KO and control
mice 20 weeks after deletion of Fto. At 20 weeks of age, adult onset
KO mice weigh, on average, 1.5 g less than controls: around 0.9 g
of this difference is not explained by the observed changes in lean
and fat mass, and may possibly be attributable to changes in
skeletal growth. Consistent with this the germline knockout male
mice showed reduced bone mineral content and density (unpub-
lished observations).
Our data clearly indicate that FTO affects body composition.
Early global loss of FTO is more severe perhaps due to critical
events during the suckling and weaning periods, and a dietary
response that leads to growth deficits. Adult onset loss of FTO
results in increased fat mass at the expense of lean body mass and
reduced weight without overt linear growth restriction.
We observed altered carbon dioxide output in adult onset KO
mice. This resulted in a large reduction in RER. That this
occurred with a reduction in lean body mass may be in keeping
with increased protein utilisation at the expense of carbohydrate.
The observed metabolic switch is consistent with the reduction in
lean body mass. How loss of FTO causes this metabolic switch is
an important question for future research. Recently, Cheung et al
(2012) have shown that FTO expression is down-regulated in vitro
by essential amino-acid deprivation [36]. Given the effects on lean
mass and RER in adult onset KO mice this may be an interesting
avenue for future investigation.
The association of FTO SNPs with food intake in the human
population suggests at-risk alleles are associated with increased
food intake [15–22]. Additionally, the increased food intake
observed in constitutive KO mice (when account is taken of the
reduced body mass) and in a mouse overexpressing Fto focus
attention on the hypothalamic centres of the brain involved in
controlling food intake [26,27,32]. However, our deletion of Fto in
the hypothalamus using AAV-Cre vectors had a relatively mild
phenotype, with reduced body weight gain probably as a result of
reduced food intake.
We previously showed that short-term AAV-shRNA knock-
down of Fto in the hypothalamic ARC of rats led to increased food
intake, although there was no effect on body weight [33]. These
Figure 7. Energy expenditure and metabolism in female adult hypothalamic KO mice. A, VO2 consumed, B, VCO2 produced, and C, energy
expenditure (EE). adjusted for variation in lean mass using multiple linear regression (ANCOVA). D, respiratory exchange ratio (RER). Female adult
AAV-Cre treated (n = 5) and sham control (n = 5) mice. Measurements were made, 5 weeks after treatment, over a 48-hour period during the dark
(lights out) and light (lights on) phases. Data are expressed as mean 6 SE and individual data points are shown. For details of the lean-mass
adjustment made in panels A,B,C, see Materials and Methods. No significant differences were found.
doi:10.1371/journal.pgen.1003166.g007
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apparent differences may, in part, be due to different hypothalamic
areas being targeted; in the present mouse-based study, the
mediobasal hypothalamus was targeted, whereas the arcuate nucleus
alone was targeted in the previous rat study [33]. In contrast, to our
AAV-Cre knockout a neural specific knockout of Fto has been
reported that used a nestin Cre to delete a floxed Fto exon 3. These
mice have an overt phenotype very similar to constitutive global KO
mice [27]. Nestin is expressed far more widely than the hypothal-
amus, and is expressed early in development (from embryonic day
7.75 [37]), which may explain the differences with our AAV-Cre
knockout. Global deletion of Fto in adult onset KO mice will target
multiple brain regions as Fto is very widely expressed [38].
FTO is expressed throughout the body and is particularly highly
expressed in many regions within the brain [1,38]. In keeping with
a gene implicated as having a potential role in appetitive
behaviour, the hypothalamic expression of Fto in response to a
variety of nutritional changes has been extensively studied [38–
42]. A clear, consistent message from these studies is difficult to
ascertain with Fto expression having been reported to be down
regulated [1,39–40], unchanged [38] and also up-regulated [41–
42] in response to fasting. These differences are likely to be a
reflection of a range of fasting duration, strain and species
differences as well as variations in tissue studied (whole hypothal-
amus vs individual regions of hypothalamus). However, it may be
that some of variability in these data is driven by a particular facet
of metabolic state of the different animals during the study period.
For example, we have recently reported that essential amino acid
starvation reduces FTO protein and mRNA levels in cell lines and
that this is reversible on re-feeding [36].
Male and female mice differ in body weight and body
composition and female mice also go through an estrous cycle of
4–6 days. The other published global germline knockouts show
clear and similar effects in both male and female mice, although the
differences in females are not as overt as in male and in the case of
the Gao et al. knockout (2010) there is as already noted gradual
convergence in female body weights over 3 to 12 weeks. Similarly
for our knockout female mice are not as strongly affected as males
(data not shown). These differences are unlikely to reflect basic
differences in the mechanism of FTO action but more likely in the
relative ability of the sexes to buffer changes in metabolism and in
sex hormone dependent difference in growth and behaviour.
The effect of adult onset global deletion of Fto on lean mass
suggests that it could be interesting to examine FTO genotype in
conditions of cachexia to see if there is a modifying effect. An
initial study in chronic obstructive pulmonary disease (COPD)
suggests variation of lung function with FTO genotype and
proposes a link with cachexia in a subset of these patients [43].
Our data indicate that FTO has a clear role in influencing body
composition and metabolic substrate utilisation within peripheral
tissues. They also show that total removal of FTO can be as
deleterious as increasing its expression, as both adult onset KO
mice and mice globally overexpressing Fto mice have increased fat
mass [32]. This suggests that in man the at-risk allele could
influence BMI either by decreasing or increasing FTO levels, or by
impairment of its proper regulation. There are possible parallels
between the early adiposity rebound observed in children with the
at-risk A allele and adult onset KO mice which show an initial
decrease in body weight before later increasing weight [10–11].
Whether FTO is a good drug target for obesity is still an open
question despite there being some undesirable effects of knocking it
out. There may be a therapeutic range of inhibition that would be
beneficial. Formally it also remains to be proven that the catalytic
activity is solely responsible for the effects that have been shown by
gene manipulation.
In conclusion, our data demonstrate that the FTO phenotype is
not linked to energy expenditure, that FTO has a role in early life
and that germline loss leads to significant lethality, that loss in
adulthood is better tolerated and leads to changes in both lean and
fat mass (through alterations in metabolism) and that hypotha-
lamic loss of Fto only explains a small part of the phenotype. Thus
our study shows a complex role for FTO both in the brain, in




All animal studies were carried out in accordance with UK
Home Office legislation and local ethical guidelines issued by the
Medical Research Council (Responsibility in the Use of Animals
for Medical Research, July 1993). Mice were kept under controlled
light (light 7am–7pm, dark 7pm–7am), temperature (2162uC) and
humidity (55610%) conditions. They had free access to water (9–
13 ppm chlorine). They were fed ad libitum on a commercial diet
(SDS Rat and Mouse No. 3 Breeding diet, RM3) containing
11.5 kcal% fat, 23.93 kcal% protein and 61.57 kcal% carbohy-
drate. Actin-cre and tamoxifen inducible ubiquitin-Cre mice were
obtained from the Jackson Laboratory (Stock name Tg(ACTA1-
cre)79Jme/J and B6.Cg-Tg(UBC-cre/ERT2)1Ejb/J, respectively).
Phenotyping tests were performed according to EMPReSS
(European Phenotyping Resource for Standardised Screens from
EUMORPHIA) standardized protocols as described at (http://
empress.har.mrc.ac.uk).
Construction of Fto Targeting Vector
The Fto exon 3 conditional knockout construct was designed to
introduce LoxP sites flanking exon 3 and a FRT flanked neomycin
resistance cassette. A MC1 driven thymidine kinase cassette
(PL253; http://recombineering.ncifcrf.gov/) was subcloned into
the XhoI site of PL451 (http://recombineering.ncifcrf.gov/) to
generate pTKNEO. Additional restriction sites (PmlI) were added
to PL451 using asymmetric overlapping oligonucleotides (Table
S7) into the NotI site of PL451 to generate p3OLI. An additional
LoxP site was inserted by asymmetric overlapping oligonucleotides
into the ClaI site of pTKNEO (Table S7). A Fto intron-two 59
recombinogenic arm of homology was amplified (3496 bp) from
R1 129 ES cell genomic DNA using Phusion High-Fidelity PCR
(Finnzymes, NEB) using the oligonucleotides 59-CATTCTTT-
TATTTTGCCTGAGTGTG-39 and 59- ATACAAAAC-
CAACGCCCAGACA-39 and subcloned into the PmeI site of
PTKNEO to generate pTKNEO59. Next Fto exon 3 was amplified
(830 bp) using the oligonucleotides 59-GCTGGGGAAAAG-
TACTGTGTAGTTT-39 and 59-ACAGACACGAGTGTGCT-
TACTCATC-39 and subcloned into the HpaI site of pTKNEO59
to generate pTKNEO59Ex3. An Fto intron three 39 recombino-
genic arm of homology was amplified (3437 bp) using the
oligonucleotides 59-TATATCTGCAGAGCACCCCTCTCC-39
and 59-ACAATCCAACAATAGCAGGAGCA-39 and subcloned
into the PmeI site of p3OLI to generate p3OLI3arm. Finally this
plasmid was digested with NotI and the 39 recombinogenic arm of
homology was cloned into the NotI site of pTKNeo59Ex3 to
generate the Fto Exon 3 targeting vector.
Gene Targeting
R1 129 embryonic stem (ES) cells were transfected with 20 mg
of SrfI linearized vector. ES cell clones were selected by
ganciclovir and G418 (Geneticin) and screened by Southern blot
analysis using approximately 10 mg of HindIII digested genomic
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DNA. A 59 probe was generated by amplification of 129 R1
genomic DNA with 59- GGCATGTTAGCTGTCTCAGCCT-39
and 59-CTGTTGACACTGCTGATTCCTG-39. A 39 probe was
generated by amplification of 129 R1 genomic DNA with 59-
CTGTTACCATGTTGTTGGGTTT-39 and 59-CAGAGC-
TAATGATACTCACTTCGC-39. Radiolabelled probes were
produced using a Rediprime II DNA labelleling system (GE
Healthcare Life Sciences).
Successfully targeted ES cell clones were injected into C57BL/
6J blastocysts (Transgenesis and Gene Targeting, MRC Harwell).
The resulting chimeras were bred to C57BL/6J mice and offspring
(F1 individuals) tested for germline transmission. Mice were
genotyped by PCR using Phusion High-Fidelity PCR (Finnzymes,
NEB) with 59- AGCGCTCACTGGAGAGTGTCTG-39 and 59-
GAGCCAGAGAGGATTTAGATGGG-39 producing wildtype
(989 bp), floxed (1184 bp) or Cre recombined knockout (237 bp)
amplification products.
Global constitutive KO allele. F1 mice were crossed to b-
actin-Cre recombinase mice (Jackson Laboratory: Stock name
Tg(ACTA1-Cre)79Jme/J) congenic to C57BL/6J and the progeny
genotyped for Cre recombinase. Subsequent mice were back-
crossed to C57BL/6J to remove Cre recombinase.
Conditional floxed allele stock. Independent F1 mice were
also crossed to a line carrying the improved thermostable Flp(e)
recombinase under the control of the b-actin promoter [44],
congenic to C57BL/6J, to remove the Neo selection cassette.
Following Flpe-mediated excision of Neo, Flp(e) recombinase was
segregated by crossing to C57BL/6J mice.
Generation of the global adult knockout and control
mice. The Fto conditional floxed allele was crossed with a
tamoxifen inducible Cre line from the Jackson laboratories
(B6.Cg-Tg(UBC-Cre/ESR1)1Ejb/J). At 6 weeks of age male mice
were treated with either 200 mg/kg tamoxifen free base solution
(MP Biomedicals, Santa Ana, CA) dissolved in corn oil 2% ethanol
solution, or an equivalent amount of vehicle by oral gavage for 5
consecutive days.
Body Mass and Composition
Body mass was measured each week on scales calibrated to
0.01 g. Analysis of body composition was performed by DEXA
using the Lunar PIXImus Mouse Densitometer (Wipro GE
Healthcare, Madison, WI) or with an Echo MRI whole body
composition analyzer (Echo Medical System, Houston, TX).
Measurement of Food Consumption
Food consumption in germline loss and adult onset loss groups
was measured when mice were housed in metabolic Techniplast
cages. Food consumption in AAV-Cre treated mice was measured
while mice were housed in home cage.
Metabolic Rate Measurements
Metabolic rate was measured at 18 weeks of age using indirect
calorimetry (Oxymax; Columbus Instruments) to determine oxygen
consumption, carbon dioxide production, respiratory exchange ratio
(RER) and heat production. Heat production (energy expenditure)
was calculated using; Heat = CV6VO2, CV = 3.815+1.2326RER
(CV, calorific value based on the observed respiratory exchange
ratio; Oxymax; Columbus Instruments).
Intraperitoneal Glucose Tolerance Test
Mice were fasted overnight (16 hours) to establish a baseline
glucose level ‘‘T0’’ (time zero). Mice were weighed, and a blood
sample collected from the tail vein after administration of local
anaesthetic (EMLA cream, Eutectic Mixture of Local Anaesthet-
ics, Lidocaine/Prilocaine, AstraZeneca, UK) using Lithium-
Heparin microvette tubes (Sarstedt, Germany). They were then
injected intraperitoneally with 2 g glucose/kg body weight (20%
glucose in 0.9% NaCl). Blood samples were taken at 60 and
120 min (or 10, 20 and 30 min) after injection. Plasma glucose was
measured using an Analox Glucose Analyser GM9 (Analox, UK).
Plasma insulin was measured using a Mercodia ultrasensitive
mouse ELISA kit (Mercodia, Sweden). AUC analysis was
performed using GraphPad Prism version 5.02 for Windows.
Stereotactic Surgery
Nine to eleven week old homozygous Fto-floxed females were
stereotactically injected with AAV vectors while under anesthesia.
The coordinates used for the injections were determined using
Paxinos et al. [45] and were 1.6 mm caudal to bregma,
60.25 mm lateral to the midline and 6.0 mm below the surface
of the skull in all cases. Using a 5 ml Hamilton syringe, 200 nl
AAV vectors were injected into each side of the hypothalamus
over a 1 min period. After delivery of the AAV vectors the needle
was left in place for 10 min to prevent reflux. Body weight
measurements were recorded every week for 8 weeks. Daily food
intake was recorded between days 14 and 24 post injection.
Immunohistochemistry
Eight weeks post injection, animals were anesthetized with
Dolethal then transcardially perfused with 20 ml PBS followed by
40 ml 10% Formalin (Sigma). Brains were dissected out and
incubated in 15% sucrose/10% formalin overnight at 4uC.
Following cryoprotection in 30% sucrose/PBS, brains were frozen
on dry-ice and stored at 280uC overnight. Serial 35 mM sections
were taken using a freezing microtome and mounted on glass
slides (VWR). Antibodies used were: FTO (custom rabbit anti
recombinant mFTO antibody, 1:3000 dilution in 5% goat serum/
0.3% Triton X-100) and Cre (Novagen, 1:1000 dilution in goat
serum/0.3% Triton X-100). Biotinylated goat-anti-rabbit IgG
(Vector Laboratories, 1:300 dilution) was used as a secondary
antibody. FTO protein was visualized using avidin-Texas Red
(Vector Labs, 1:50 dilution in PBS) and sections were counter-
stained using DAPI. Cre protein was visualized using the
Vectastain ABC elite kit and VIP peroxidase kit (Vector Labs).
Western Blot Analysis and Antibodies
Western blots were performed on 50 ug of total proteins using a
custom made rabbit anti recombinant mFTO antibody. Detection
was performed using ultrasensitive horseradish Enhanced Chemi-
luminescence Plus (ECL plus; Amersham).
Statistics
Error bars show the standard error (SE). Unless otherwise
stated, p-values correspond to a Welch t-test of the null hypothesis
of no difference between genotypic groups. R (http://www.r-
project.org/) was used for the statistical analysis and presentation
of results.
Correction for body size. When comparing some pheno-
types across (treatment-genotype) groups, adjustment was made
for variation in lean mass using multiple linear regression analysis
(ANCOVA). Phenotypes for which this adjustment was made
were: VO2 consumed, VCO2 produced, and energy expenditure
(EE). The linear model used was:
yi~bg(i)zclizei
where
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N i~1,:::,n indexes mouse,
N yi denotes the phenotype of mouse i,
N g(i)[ A,Bf g denotes the (treatment-genotype) group of mouse
i,
N the bg(i) denote the main group effects





N c is the coefficient for lean mass in the linear model
N the ei are mutually independent identically distributed zero-
mean Gaussian random measurement errors.
Table S3 (indirect calorimetry analysis) and Figure 2, Figure 5
and Figure 7 (indirect calorimetry scatter plot data) show estimates
for bA, bB, and bB{bA, as well as a p-value for the test of the
hypothesis bB~bA. For the corrected phenotypes, the points
plotted in Figure 2, Figure 5 and Figure 7 (indirect calorimetry
scatter plot data) are lean mass corrected using the least-squares
estimate of c (i.e. the points yi{ĉli are plotted).
This approach was also applied to lean and fat mass adjustment
for body weight (Table S2).
Repeated-measures ANOVA. Time-course data were ana-
lysed using the repeated-measures ANOVA model [46]:
yit~azbg(i)zd½g(i),tzuizeit
where
N i~1,:::,n indexes mouse,
N t~1,:::T indexes time point,
N yit denotes the phenotype of mouse i at time point t,
N a denotes an intercept term
N g(i)[ A,Bf g denotes the (treatment-genotype) group of mouse
i,
N the bg(i) denote the main group effects (with the constraint
bA:0)
N the d½g(i),t denote interactions between group and time (with




N ui is the random effect for mouse i (these random effects model
the correlation between repeated measures), with the ui
mutually independent identically distributed zero-mean Gauss-
ian random variables, and
N the eit are mutually independent identically distributed zero-
mean Gaussian random measurement errors.
The model was fitted using the lmer() function in the lme4 R
package [47]. The null hypothesis of no main genotypic effect (i.e.
that bA~bB~0 for both groups) was tested against the alternative
hypothesis under which bB was unconstrained. The test was based
on the asymptotic x21 null distribution of {2 logL, where L
denotes the likelihood ratio. To supplement the repeated-measures
analysis, Welch t-tests were performed separately at each time
point (Tables S1, S4, S5, S6 and S8).
Supporting Information
Figure S1 Recombinase Mediated Excision of Neo and Fto Exon
3. A. Schematic of the generation of WT, conditional knock-out
(Neo removed by Flp recombination; Fto+/Flox) and knockout (exon
3 deletion; Fto+/2) mice. Southern blot analysis of targeted ES
clones. Genomic DNA digested with HindIII and probed with a
59external Fto probe to confirm targeting (Tg) of the Fto locus.
WT produces a 12.5 kb band whereas the targeted locus
generates a 7.2 kb band. B. Representative immunoblot of
FTO (56 kDa) and actin (loading control, 42 kDa) in adult brain,
liver and 17.5 dpc embryo body, from Fto2/2, Fto+/2 and WT
mice.
(DOCX)
Figure S2 Loss of FTO in male global adult onset KO mice.
Immunoblot demonstrating loss of FTO protein in whole brain,
epigonadal white adipose tissue (Epi WAT) and liver of adult onset
KO mice but not in control mice (tamoxifen-treated Cre and
vehicle-treated). Tissue collected at 20 weeks of age (14 weeks post
treatment).
(DOCX)
Figure S3 FTO expression in female Adult hypothalamic KO
mice. A & B Consecutive sections through the hypothalamus of a
mouse unilaterally injected with AAV-Cre vectors showing Cre
recombinase expression (A, purple staining) and FTO expression
(B, red staining). FTO expression is absent in the region of the
brain where Cre expression is found. C–E Representative images
showing normal FTO protein expression (red staining) within the
hypothalamus of a sham injected mice 8 weeks after surgery. F–H
Representative images showing dramatically reduced Fto protein
expression 8 weeks after injection of AAV-Cre vectors into the
mediobasal hypothalamus.
(DOCX)
Figure S4 Hypothalamic protein expression 8 weeks post
surgery in female adult onset hypothalamic KO mice. A
Representative image showing a western blot to detect
expression of Fto, Beta Tubulin, GFP or Cre in the brains of
female homozygous floxed mice injected with either an AAV-
GFP (Sham) or AAV-Cre. 8 weeks following injection, mice
were sacrificed, their hypothalamus and cortex sub-dissected
and proteins extracted using RIPA buffer. GFP expression was
only detected in the hypothalmi of mice injected with an AAV-
GFP (Sham) and Cre expression was only detected in the
hypothalmi of AAV-Cre injected mice. B Image J software was
used to quantify the intensity of Fto and Beta tubulin protein
bands from 2 animals. When normalised for Beta Tubulin
expression, an approximate 50% decrease in Fto expression was
seen in the hypothalami, but not cortex, of AAV-Cre injected
mice.
(DOCX)
Figure S5 Energy expenditure in female adult onset hypotha-
lamic KO mice. A, VO2 consumed, B, CO2 produced. Data are
expressed as mean 6 SE. Female adult AAV-Cre treated (n = 5)
and sham control (n = 5) mice. Measurements were made, 5 weeks
after treatment, over a 48-hour period during the dark (lights out)
and light (lights on) phases.
(DOCX)
Table S1 Time by time ANOVA analysis of weight in global
germline Fto KO mice. s.e, standard error.
(DOCX)
Table S2 Analysis of fat and lean mass data either as raw data,
data normalised by multiple linear regression (ANCOVA) for body
weight or by % of body weight. GG, Global Germline Knockout;
GAO, Global Adult Onset knockout; AAV, hypothalamic adult
onset knockout using AAV Cre, s.e, standard error.
(DOCX)
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Table S3 Energy expenditure phenotypes across (treatment-
genotype) groups, with the exception of RER, adjustment was
made for variation in lean mass using multiple linear regression
(ANCOVA). GG, Global Germline Knockout; GAO, Global
Adult Onset knockout; AAV, hypothalamic adult onset knockout
using AAV Cre, Light or dark phase; day or night, Tam;
Tamoxifen, s.e; standard error.
(DOCX)
Table S4 Time by time ANOVA analysis of weight in global
adult onset mice. s.e, standard error.
(DOCX)
Table S5 Time by time ANOVA analysis of weight in
hypothalamic adult onset mice. s.e, standard error.
(DOCX)
Table S6 Time by time ANOVA analysis of baseline standard-
ised weight in hypothalamic adult onset mice. s.e, standard error.
(DOCX)
Table S7 Oligonucleotides for introducing 59 LoxP site (LoxPT,
LOXPB) and oligonucleotides for introducing additional restric-
tion sites into PL451 (FTO3CST, FTO3CSB).
(DOCX)
Table S8 Repeated measures ANOVA analysis of body weight.
GG, Global Germline Knockout; GAO, Global Adult Onset
knockout; AAV, hypothalamic adult onset knockout using AAV
Cre, s.e, standard error.
(DOCX)
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